91Ï㽶ÊÓƵ

91Ï㽶ÊÓƵ today announced that it plans to expand its Waigaoqiao Free Trade Zone (FTZ) facility in Shanghai, China, to increase capacity for temperature-controlled storage and distribution of clinical supplies.

91Ï㽶ÊÓƵ today announced that it has been officially recognized by the Top Employers Institute as a Top Employer 2022 in both the United States and the United Kingdom.

91Ï㽶ÊÓƵ today announced that it has completed a $10 million expansion at its Malvern, Pennsylvania, and Dartford, U.K., facilities, to provide advanced containment capabilities for the micronization of highly potent drug compounds.

91Ï㽶ÊÓƵ today announced the launch of its new Xpress Pharmaceutics® service, designed to accelerate the development of oral drugs through Phase 1 clinical studies.

91Ï㽶ÊÓƵ today announced that it has increased cold chain packaging capabilities at its Philadelphia facility to support increased demand for the distribution of biologic drugs, and advanced cell and gene therapies.

91Ï㽶ÊÓƵ today announced that its Board of Directors has appointed Alessandro Maselli, currently President and Chief Operating Officer, as the company’s next President and Chief Executive Officer, effective July 1, 2022.

NurOwn is BrainStorm’s autologous cellular therapy being developed for the treatment of amyotrophic lateral sclerosis (ALS), progressive multiple sclerosis (PMS) and other neurodegenerative diseases.

The selection follows a seven-month formulation development program conducted by 91Ï㽶ÊÓƵ, in which the API was screened for ideal formulation conditions, with a number of potential excipients, to come up with a drug product that suits ProtoKinetix’s needs.

91Ï㽶ÊÓƵ today announced that three of its experts will be speaking on current market trends and strategies within the industry at two upcoming conferences, Outsourcing in Clinical Trials East Asia, and Outsourcing in Clinical Trials Southern California 2021.